Pantheon Vision and Eyedeal Medical enter collaborative agreement to develop bioengineered corneal implant

Author(s):

Martin David Harp

Key Takeaways

Pantheon Vision and Eyedeal Medical collaborate to commercialize bioengineered corneal implants, targeting corneal blindness elimination.
Pantheon has engaged in multiple FDA meetings to support a Premarket Approval submission for their corneal implants.
The partnership aims to overcome limitations of human-donated corneal tissue, including low success rates and limited availability.
The collaboration is expected to revolutionize vision restoration, potentially eliminating the need for corneal donations globally.

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

(Image Credit: AdobeStock/David)

Pantheon Vision has entered into a collaboration agreement with manufacturer Eyedeal Medical to advance the production and commercialization of Pantheon Vision’s bioengineered corneal implant.

At the beginning of 2025, Pantheon completed its third meeting with the US Food and Drug Administration (FDA) review team, after previously completing 2 pre-submission meetings with the organization. The meetings were for guidance on the initial stages of pre-clinical and clinical work supporting a Premarket Approval (PMA) submission for the company’s bioengineered corneal implants to eliminate corneal blindness.

Guo Guangxu, founder and CEO of Eyedeal Medical, and John Sheets, Jr, PhD, president and CEO of Pantheon Vision commented on the partnership in a press release from Pantheon.

“Pantheon Vision has assembled a world-leading ophthalmic design team whose groundbreaking mindset has enabled the bold development of a revolutionary single-piece polymer artificial cornea for vision restoration,” said Guangxu. “This innovation, upon commercialization, will fundamentally eliminate the need for corneal donations while bringing new hope to global patients requiring corneal transplantation."

“This agreement is a critical step for Pantheon Vision as we advance our mission of developing a bioengineered corneal solution to treat and restore vision for people around the world,” said Sheets Jr “We are grateful for the partnership with Eyedeal Medical and are extremely optimistic that together we can create an innovative solution that will provide meaningful benefits to patients suffering from corneal blindness.”

Human donated tissue has less than a 50% success rate at 5 years, among other issues such as short shelf life and insufficient tissue available. The company aims to tackle these issues with its bioengineered corneal implants.

References:

Pantheon Vision signs collaboration agreement with Eyedeal Medical to develop bioengineered corneal implant. Published March 27, 2025. Accessed March 27, 2025. https://www.businesswire.com/news/home/20250327308058/en/Pantheon-Vision-Signs-Collaboration-Agreement-with-Eyedeal-Medical-to-Develop-Bioengineered-Corneal-Implant